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Chromosome 9p21 gene copy number in Ewing’s sarcoma family of tumour (ESFT) cell lines and primary ESFT has been evaluated
using Multiplex Ligation-dependent probe amplification, and the clinical significance of CDKN2A loss and p16/p14
ARF expression
investigated. Homozygous deletion of CDKN2A was identified in 4/9 (44%) of ESFT cell lines and 4/42 (10%) primary ESFT; loss of
one copy of CDKN2A was identified in a further 2/9 (22%) cell lines and 2/42 (5%) tumours. CDKN2B was co-deleted in three (33%)
cell lines and two (5%) tumours. Co-deletion of the MTAP gene was observed in 1/9 (11%) cell lines and 3/42 (7%) tumours. No
correlation was observed between CDKN2A deletion and clinical parameters. However, co-expression of high levels of p16/p14
ARF
mRNA predicted a poor event-free survival (P¼0.046, log-rank test). High levels of p16/p14
ARF mRNA did not correlate with high
expression of p16 protein. Furthermore, p16 protein expression did not predict event-free or overall survival. Methylation is not a
common mechanism of p16 gene silencing in ESFT. These studies demonstrate that loss (homozygous deletion or single copy) of
CDKN2A was not prognostically significant in primary ESFT. However, high levels of p16/p14
ARF mRNA expression were predictive of
a poor event-free survival and should be investigated further.
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The Ewing’s sarcoma family of tumours (ESFT) is defined by the
presence of an EWS-ETS gene rearrangement involving the EWS
gene on chromosome 22q12 with one of a number of ETS genes;
most frequently with FLI1 on chromosome 11q24 (Turc-Carel et al,
1983; Delattre et al, 1994). These gene rearrangements generate
aberrant transcription factors that are important in the develop-
ment and maintenance of the ESFT malignant phenotype (May
et al, 1993; Teitell et al, 1999; Rorie and Weissman, 2004).
However, up to 80% of primary ESFT have nonrandom secondary
chromosome changes (Mugneret et al, 1988; Kullendorff et al,
1999; Zielenska et al, 2001), several of which are reported to be
prognostically significant.
Loss of the cell-cycle regulatory gene CDKN2A exon 1a (which
codes for p16) has been reported in between 13 and 30% of ESFT
(Kovar et al, 1997; Tsuchiya et al, 2000; Wei et al, 2000; Huang
et al, 2005). CDKN2A exon 1b (p14
ARF) is often co-deleted with
CDKN2A exon 1a (Kovar et al, 1997; Tsuchiya et al, 2000; Wei et al,
2000). Loss of p16 protein expression has also been reported in a
small panel of ESFT (Maitra et al, 2001), although the prognostic
significance of this loss remains unclear. Although homozygous
deletion of CDKN2A exon 1a has been described, the frequency
and impact of single gene copy number changes has not been
investigated.
Gene copy number in up to 45 nucleic acid sequences can be
analysed using multiplex ligation-dependent probe amplification
(MLPA; Schouten et al, 2002) and has been successfully exploited
to identify constitutive gene copy number changes in many genes
including the BRCA1 gene in breast and ovarian cancer families
(Hogervorst et al, 2003; Montagna et al, 2003; Bunyan et al, 2004;
Hartmann et al, 2004) and the MSH2 and MLH1 genes in patients
with Lynch syndrome (Gille et al, 2002; Nakagawa et al, 2003;
Taylor et al, 2003; Bunyan et al, 2004). More recently, the
technique has been applied to the analysis of copy number changes
in tumours (Aveyard and Knowles, 2004).
The aims of this study were to investigate the frequency of
homozygous and single copy loss of CDKN2A and other genes
located on chromosome 9p21 in primary ESFT. The methylation
status of the p16 promoter was also assessed, and the prognostic
significance of CDKN2A loss, p16/p14
ARF mRNA and p16 protein
expression in primary ESFT investigated.
MATERIALS AND METHODS
Cell lines and clinical samples
Nine ESFT cell lines (A673, RDES, TC-32, TTC-466, SK-N-MC,
SKES1, GROH1, STAET1 and STAET11), three neuroblastoma
(IMR-32, SK-N-SH and SH-SY5Y) and one colorectal carcinoma
(SW480) cell lines were investigated. TC-32, RD-ES, A673, SK-N-
MC, SKES1, TTC-466, SH-SY-5Y and SK-N-SH cells were cultured
as described previously (Myatt et al, 2005). GROH1, STAET1 and
STAET11 were grown in RPMI 1640 (Sigma, Dorset, UK) contain-
ing 10% fetal calf serum (FCS; SeraLab, Sussex, UK), SW480 cells
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sin Dulbecco’s modified eagle’s medium (DMEM; Sigma) and 10%
FCS and IMR-32 cells in 1:1 DMEM:RPMI 1640. GROH1, STAET1
and STAET11 cells were kind gift from Dr H. Kovar (Children’s
Cancer Research Institute, Vienna, Austria).
Diagnosis of ESFT (n¼42) was confirmed by reverse tran-
scriptase (RT)-PCR for the EWS-ETS gene rearrangements (36/42)
or immunohistochemistry for MIC-2 (CD99; 6/42). The presence of
metastases were detected by conventional imaging and examina-
tion of bone marrow by light microscopy. Informed consent was
obtained for the use of tumour material for biological studies.
Ethical approval was obtained from the Leeds NHS Trust Ethics
Committee (MREC 98/0/44) and the CCLG tumour bank (MREC
98/4/023).
Extraction of DNA and RNA
Total RNA was extracted from cell lines using Ultraspec
TM
(Biotecx; Houston, TX, USA; Burchill et al, 1994), and DNA using
the DNeasy Tissue kit (Qiagen, West Sussex, UK) according to
manufacturer’s instructions.
Frozen sections of primary ESFT were stained with haematox-
ylin and eosin and tumour cells isolated by laser-capture micro-
dissection, using the PixCellt laser-capture micro-dissection
system (LCM; Arcturus, Sunnyvale, CA, USA). DNA and RNA
were extracted from the isolated tumour cells using the QIAamp
DNA Micro kit (Qiagen) and the PicoPuret RNA Isolation Kit
(Arcturus), respectively.
The quantity and quality of RNA and DNA were measured by
assessment of absorbance at 260 and 280nm (Nanodrop, Labtech
International; Ringmer, East Sussex, UK).
Multiplex ligation-dependent probe amplification
Multiplex ligation-dependent probe amplification was performed
on DNA diluted in TE buffer (5ml; 10mM Tris–HCl (pH 8.2) and
1m M EDTA), using the 9p21 MLPA SALSA P024 CDKN2A/2B
region Deletion Test Kit (MRC Holland; Amsterdam, The Nether-
lands) according to manufacturer’s instructions. Bovine serum
albumin (1mg; Sigma) was added to DNA from LCM tumour
samples to improve amplification efficiency. DNA from cell lines
(200ng) was amplified for 33 cycles and from tumours (21–
201ng) for 36 cycles on the GeneAmp PCR System 9700 thermal
cycler (Applied Biosystems, Warrington, UK). Data was analysed
using the ABI PRISM
s 3100 Genetic Analyser and POP4 Genescan
polymer, and MLPA data collected using Genescan software
(Applied Biosystems). Peak heights of each probe were compared
to those of the average of two normal control samples (previously
determined to be wild type for all of the genes tested) to obtain a
dosage quotient (DQ). The DQ represents the gene dosage of each
probe and was calculated using the following formula:
DQ¼((A/B)/(A0/B0)) where A is the peak height of the patient
test probe A, B is the peak height of the patient internal control B
and A0 and B0 are the peak heights of the same probes from the
average of the normal control samples. The DQ was calculated for
each test probe in comparison to each internal control probe and
the mean average DQ for each test probe calculated. The standard
deviation of the DQ of a test probe compared to each internal
control probe was also calculated. A DQ of 1¼both copies of the
gene are present, DQ¼0.5 one copy of the gene is deleted,
DQ¼41.5 is indicative of gene duplication and DQ¼0 both
copies of the gene are absent.
Methylation-specific PCR
DNA (500ng cell line, 100ng of primary ESFT) in a total volume of
45ml was treated with the EZ DNA Methylation Kit (Cambridge
BioScience, Cambridge, UK) and eluted into 10mlo fM - E l u t i o n
Buffer. Methylation-specific PCR was performed for the p16
promoter region on cell lines and tumours without homozygous
deletion of CDKN2A. Modified DNA (2ml cell line, 4ml primary
ESFT) was amplified in a 50ml PCR containing 300ng of sequence-
specific primers (Herman et al, 1995), 0.2mM dNTPs (Amersham
Biosciences, Buckinghamshire, UK), 1.5mM MgCl2 (Sigma) and 1U
of AmpliTaq Gold DNA polymerase in 1 AmpliTaq Reaction Buffer
II (Applied Biosystems). Amplitaq Gold was activated by heating
(951C 10min), and DNA amplified using 35 cycles of 951C 30s,
Table 1 Summary of the status of the genes located to chromosome 9p21 in ESFT and neuroblastoma cell lines
Cell line
Probe TC-32 RDES TTC-466 SKES1 GROH1 SK-N-MC A673 STAET1 STAET11 IMR-32 SH-SY-5Y SK-N-SH
TEK ++ + 7 ++ 7 ++ + ++
ELAVL2 77 + 7 ++ 7 ++ + ++
p15 promotor/exon 1 77 + 7 ++      ++ +
p15 exon 1 77 + 7 ++      ++ +
p15 intron 77 + 7 ++      ++ +
0.5kb upstream of p14
ARF 77 + 7 ++      ++ +
p14
ARF exon 1b 77 + 7 ++      ++ +
Intron between p14
ARF and p16
exon 1
77 + 7 ++      ++ +
Second intron probe between
p14
ARF and p16 exon 1
77 + 7 ++      ++ +
p16 exon 1   7 + 7 ++      ++ +
p16 exon 2   7 + 7 ++      ++ +
p16 exon 3   7 + 7 ++      ++ +
MTAP probe 3; end of MTAP gene   7 + 7 ++ 7 ++ + ++
MTAP probe 2   7 + 7 ++ 7 ++ + ++
MTAP probe 1; start of MTAP gene 77 + 7 ++ 7 ++ + ++
KIAA1354 + 7 + 7 ++ 7 ++ + ++
IFNW1 + 7 + 7 ++ 7 ++ + ++
IFNB1 + 7 + 7 ++ 7 ++ + ++
MLLT3 probe 2 + 7 + 7 ++ 7 ++ + ++
MLLT3 probe 1 + 7 + 7 ++ 7 ++ + ++
FLJ00026 + 7 + 7 ++ + + +++ +
ESFT¼Ewing’s sarcoma family of tumours, MLPA¼multiplex ligation-dependent probe amplification. DNA was extracted from the cell lines and subjected to MLPA using the
9p21 kit. +¼probe copy number wild type (two copies present), ¼complete deletion of target sequence, 7¼hemizygous deletion (one copy present).
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Figure 1 Multiplex ligation-dependent probe amplification analysis of ESFT DNA. DNA was extracted from the (A) SK-N-MC, (B) TC-32 and (C) RDES
cell lines and analysed for deletions of genes at the 9p21 region by MLPA. (i) Amplification products were separated by electrophoresis and analysed using
Genescan software. (ii) The 9p21 probe peak heights are displayed relative to control probe peak heights to identify gene copy number. The 9p21 genes
tested are displayed on the x axis and the dosage quotient (DQ) is displayed on the y axis. (iii) Diagram showing the gene copy number of genes located at
chromosome 9p21, E – exon. The SK-N-MC cell line exhibits a wild-type copy number of all genes tested, MLPA has identified both homozygous and single
copy deletion of genes in the TC-32 cell line and the RDES cell line has a single copy deletion of the majority of the genes tested.
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s601C (unmethylated PCR) or 651C (methylated PCR) 30s and
721C 1min, with a final extension of 721C 4min.PCRproducts
were separated on a 2% agarose gel, stained with ethidium bromide
(0.5mg/ml) and visualised under ultraviolet light.
Real-time RT-PCR
RNA (250ng cell line, 5ng primary ESFT) was reverse-transcribed
with 5U of murine leukaemia virus RT in 8U of RNA guard, 1mM
dNTP, 8mM MgCl2, 0.3mg random hexamer primers and 1 PCR
buffer (10mM Tris–HCl (pH 8.3), 50mM KCl; Applied Biosystems)
made up to a total volume of 5ml with diethyl pyrocarbonate
(DEPC)-treated H2O. The resulting cDNA was added to 20mlo f
PCR mix containing a final concentration of 1 TaqMan Universal
PCR Master Mix (containing AmpliTaq gold DNA Polymerase;
Applied Biosystems) with 1  CDKN2A TaqMan Gene Expression
Assay (this assay contains primers and probe to amplify exons 2
and 3 of the CDKN2A gene encoding both p16 and p14
ARF mRNA;
Applied Biosystems) or primers (100nM) and TaqMan probes
(100nM labelled with 50-FAMt and 30-TAMRAt) to amplify b2-
microglobulin mRNA (b2M) in DEPC-treated H2O.
b2M forward primer 50-GAGTATGCCTGCCGTGTG-30,
b2M reverse primer 50-AATCCAAATGCGGCATCT-30,
b2M probe 50-CCTCCATGATGCTGCTTACATGTCTC-30
Samples were amplified in triplicate (1 951C for 10min,
followed by 40 cycles of 951C 15s, 601C 1min) and analysed
on the ABI PRISM 7700 Sequence Detector (Applied Biosystems).
Negative controls included samples in which template or RT was
absent; RNA extracted from the SK-N-MC cell line was included as
a reference sample. The fold change in expression was determined
using the comparative CT method (see www.appliedbiosystems.
com). Expression was scored as low or high based on a cutoff of
0.1; this was selected as it corresponded to the upper quartile of the
ratios in the data.
Immunohistochemistry for p16
Frozen tumour from 37 patients at diagnosis was available for
immunohistochemistry. Sections (5mm) were fixed on glass slides
for 2 2min in methanol:acetone (50:50), allowed to air dry and
expression of p16 examined using a p16 monoclonal antibody
(1:1000 for 1h; Ab-7; Labvision, Fremont, CA, USA) and the
catalysed signal amplification system (CSA System; DakoCytoma-
tion, Cambridgeshire, UK) according to manufacturer’s instruc-
tions. Endogenous biotin or biotin-binding proteins were blocked
using the Avidin Biotin blocking kit (Vector Laboratories,
Peterborough, UK) according to manufacturer’s instructions, and
endogenous peroxidase activity blocked using 3% hydrogen
peroxide in water for 5min (CSA System). Sections were counter-
stained with haematoxylin, dehydrated and mounted in DePex
mounting medium (VWR International, Leicestershire, UK). p16
expression was examined by light microscopy and scored in
ii
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Figure 1 Continued.
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stumours as absent (negative), expressed or highly expressed. The
percentage of cells positive for p16 was calculated by counting the
number of positive cells per 100 cells in three fields.
Statistical analyses
The prognostic value of CDKN2A gene status, p16/p14
ARF mRNA
and p16 protein expression was evaluated using the log-rank test.
Overall survival was calculated as the time from diagnosis to the
date last seen, regardless of the number of events that may have
occurred. Event-free survival was defined as the time from
diagnosis to the time of first event; first event could be relapse,
death or date last seen for surviving patients. Associations between
CDKN2A gene status, p16/p14
ARF mRNA expression and clinical
features were evaluated using Fisher’s exact test. Statistical analysis
was performed using the SAS statistical software (SAS Institute
Inc., Cary, NC, USA).
RESULTS
CDKN2A status detected by MLPA in ESFT cell lines
The 9p21 MLPA SALSA P024 CDKN2A/2B region Deletion Test Kit
contains 17 control probes, two of which are located on
chromosome 8 (8q24 and 8p23). Analysis of the MLPA results
for the ESFT cell lines revealed that in 8/9 one or both of the two
control probes located to chromosome 8 were duplicated, leading
to an inaccurate assessment of the copy number of the 9p21
probes. Cytogenetic analysis identified gain of chromosome 8 in 7/
8 of these cell lines (data not shown), consistent with previous
literature (Armengol et al, 1997; Tarkkanen et al, 1999; Hattinger
et al, 2002). Therefore the control probes on chromosome 8 were
excluded when analysing data from ESFT. Gain or loss of
additional control probes on 5q, 1p, 7p, 11p, 14q, 5q, 11q, 17p,
7q, 22q, 2p and 10p were not identified across ESFT DNA.
All 9p21 genes were wild type in the three neuroblastoma cell
lines and 3/9 (33%) of the ESFT cell lines. Homozygous deletion of
CDKN2A was identified in 4/9 (44%) ESFT cell lines, co-deletion of
CDKN2A exon 1b and CDKN2B occurred in three (33%) and
co-deletion of MTAP in 1/9 (11%). Single copy deletion of
CDKN2A was identified in further 2/9 (22%) ESFT cell lines, and
of further genes in four cell lines (in two of these homozygous
deletions had been identified) (Table 1, Figure 1). Deletions of
CDKN2A were more frequent in ESFT cell lines (44%) than in
primary tumour material (10%; see below), consistent with the
literature (Kovar et al, 1997). This could reflect the selection of
tumour cells for growth in culture or accumulation of genetic
abnormalities during culture.
Expression of p16/p14
ARF mRNA and p16 promoter
hypermethylation in ESFT cell lines
Hypermethylation of the p16 promoter was not observed in any of
the ESFT cell lines where the CDKN2A status was wild type or
single copy deleted (Figure 2A).
Cell lines with homozygous deletion of CDKN2A did not express
p16/p14
ARF mRNA (Figure 3A). Although expression of p16/
p14
ARF across the cell lines was heterogeneous, there was no
correlation with CDKN2A copy number (P¼0.13; analysis of
variance (ANOVA) with t-test). The reference sample (SK-N-MC)
had the highest level of p16/p14
ARF expression; this cell line is p53
null consistent with the hypothesis that p14
ARF expression is
elevated in p53-deficient cell lines (Nakagawa et al, 2003; Myatt
et al, 2005). p53 was expressed in all other cell lines except the
CDKN2A-deleted A673.
CDKN2A status in primary ESFT samples
Eighty-six percent (36/42) of primary ESFT were wild-type
CDKN2A. Homozygous deletion of CDKN2A was identified in
4/42 (10%) of tumours, co-deletion of CDKN2A exon 1b in three
and CDKN2B in two of these samples. Co-deletion of MTAP was
observed in 3/42 (7%) tumours. Single copy loss of 9p21 genes was
observed in 3/42 (7%) tumours, two of these single copy losses
were of the CDKN2A gene (5%; Table 2). There was no relationship
between CDKN2A gene status and overall (P¼0.42, log-rank test)
or event-free (P¼0.88) survival when patients with homozygous
deletion tumours were compared to those that were wild type. No
association was observed between CDKN2A gene status and the
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Figure 2 Methylation-specific PCR analysis of the promoter region of p16. DNA extracted from (A) ESFT cell lines and (B) primary tumour samples was
treated with the EZ DNA Methylation Kit and subjected to MSP. The presence of a PCR product in lanes labelled U indicates the presence of unmethylated
p16 promoter regions, the presence of a PCR product in lanes labelled M indicates the presence of p16 promoter hypermethylation. Treated DNA
extracted from the IMR-32 and SW480 cell lines was used as negative and positive controls, respectively, for p16 promoter hypermethylation.
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spresence of metastatic disease at diagnosis (P¼0.21, Fisher’s
exact test).
The median overall and event-free survival for patients wild type
for CDKN2A was not estimable and 42 months (95% confidence
interval (CI)¼15 N), respectively, the median overall and event-
free survival for patients with homozygous deletion of CDKN2A
was 36 months (95% CI¼19 N) and 34 months (95%
CI¼14 N), the median overall and event-free survival times
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Figure 3 Comparison of p16/p14
ARF levels in ESFT cell lines and primary samples. (A) RNA was extracted from ESFT cell lines and p16/p14
ARF and
b2-microglobulin expression levels were determined by real-time RT-PCR. Expression in each cell line was normalised to expression of b2-microglobulin and
relative to a reference sample (SK-N-MC); expression levels are presented as a fold change in expression. (B) RNA was extracted from cells isolated by
laser-capture micro-dissection from 5mm sections of primary ESFT. Expression of p16/p14
ARF and b2-microglobulin was determined by real-time RT-PCR;
expression in each tumour was normalised to expression of b2-microglobulin and relative to a reference sample (SK-N-MC). (C) Kaplan–Meier survival plot
to compare the event-free survival of patients with tumours that had a high p16/p14
ARF mRNA expression level (X0.1) to that of patients with tumours that
had a low p16/p14
ARF mRNA expression level (o0.1), P¼0.043; log-rank test. Circles define censored events.
p16 in ESFT
SC Brownhill et al
1919
British Journal of Cancer (2007) 96(12), 1914–1923 & 2007 Cancer Research UK
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
swere not estimable for patients with single copy CDKN2A
deletions.
Expression of p16/p14
ARF mRNA, and p16 promoter
hypermethylation in primary ESFT
Tumour expression of p16/p14
ARF mRNA was heterogeneous
(Figure 3B) and although there was no correlation between
expression and CDKN2A copy number (P¼0.35; ANOVA with
t-test), homozygous deletion of the CDKN2A gene (samples 07/01,
27/02, 04/03 and 36/05) resulted in loss of p16/p14
ARF mRNA
expression.
The prognostic significance of p16/p14
ARF mRNA expression
was assessed in cases (n¼33), where clinical outcome information
was available. The median overall and event-free survival for
patients with tumours expressing high levels of p16/p14
ARF mRNA
(X0.1, n¼6) were not estimable and 872 days (95% CI¼296–
1290 days), respectively. The median overall and event-free
survival times for patients with tumours expressing low levels of
p16/p14
ARF mRNA (o0.1, n¼26) were not estimable. No relation-
ship was observed between p16/p14
ARF mRNA expression and
overall survival (P¼0.54, log-rank test); however, patients with
tumours expressing low levels of p16/p14
ARF mRNA (o0.1) were
found to have a significantly better event-free survival than
patients with tumours expressing very high levels of p16/p14
ARF
mRNA (X0.1; P¼0.046, log-rank test; Figure 3C).
Hypermethylation of the p16 promoter was not observed in any
of the 35 tumours examined; tumours with homozygous deletion
of CDKN2A were omitted from the analysis (Figure 2B).
Expression of p16 protein in primary ESFT
Immunohistochemistry for p16 protein was performed on 37
primary ESFT. p16 was not detected in 3/4 tumours that were
homozygously deleted for CDKN2A (Figure 4A). In one tumour
(36/05) p16 was focally expressed in 23% of tumour cells. In those
tumours that were p16 wild type, p16 was not expressed in 6/33
tumours.
p16 protein expression was nuclear and cytoplasmic, and in the
majority of tumours (n¼26) restricted to focal hotspots within the
tumour (Figure 4B). Within these hotspots p16 was expressed
within 1–23% of cells. These tumours included 3 with high p16/
p14
ARF mRNA. Two tumours expressed high levels of p16 protein
throughout the tumour; in tumour 38/01 25% of cells expressed
p16 and in tumour 15/05 47% of cells expressed p16 (Figure 4C).
Both these tumours had high levels of p16/p14
ARF mRNA. Protein
expression of p16 was not prognostically significant of overall
(P¼0.78) or event-free (P¼0.70) survival in the study group.
There was no correlation between p16 protein and p16/p14
ARF
mRNA expression.
DISCUSSION
The frequency of homozygous deletions of CDKN2A detected by
MLPA in ESFT cell lines (44%) and primary tumours (10%) is
consistent with the literature using more established methods
including Southern blot (Kovar et al, 1997; Tsuchiya et al, 2000;
Wei et al, 2000), PCR (Tsuchiya et al, 2000), and fluorescent in situ
hybridisation (Huang et al, 2005). Using MLPA it was also possible
to detect co-deletion of the cell-cycle regulatory genes CDKN2B
(encoding p15) and CDKN2A exon 1b (encoding p14
ARF). We
therefore conclude that MPLA is a robust, low-cost, rapid, high-
throughput method to analyse the status of multiple genes in
frozen primary tumour; it is not reliably informative in paraffin-
embedded material (results not shown). Most importantly for
precious tumour samples, the amount of nucleic acid required for
MLPA is small (B20ng of DNA, equivalent to approximately 3000
cells or 6000 single copy target sequences). However, it is essential
that DNA is isolated from a pure tumour cell population, as MLPA
Table 2 Summary of the status of the genes located to chromosome 9p21 in ESFT where abnormalities were identified
Tumour
Probe 04/03 07/01 27/02 72/03 29/99 36/05
TEK ++++++
ELAVL2 ++++++
p15 promotor/exon 1 +   ++7  
p15 exon 1 +   ++7  
p15 intron +   + 7  
CpG island at p14
ARF promotor +   + 7  
0.5kb upstream of p14
ARF +   + 7  
p14
ARF exon 1b +   + 7  
Intron between p14
ARF and p16 exon 1 +   + 7  
Second intron probe between p14
ARF and p16 exon 1 +   + 7  
p16 exon 1 a +   77 
p16 exon 1 a +   77 
p16 exon 2    + 7  
p16 exon 3    + 7  
MTAP probe 3; end of MTAP gene   ++7  
MTAP probe 2   ++7  
MTAP probe 1; start of MTAP gene +   ++7  
KIAA1354 +++++7
IFNW1 +++++7
IFNB1 +++++7
MLLT3 probe 2 + + + + + +
MLLT3 probe 1 + + + + + +
FLJ00026 ++++++
ESFT¼Ewing’s sarcoma family of tumours, LCM¼laser-capture micro-dissection system, MLPA¼multiplex ligation-dependent probe amplification. DNA was extracted from
tumour cells isolated by LCM from 42 primary ESFT and subjected to MLPA using the 9p21 kit. Wild-type copy number of all of the genes tested was observed in 36 ESFT (data
not shown), six ESFT exhibited homozygous or single copy deletion of one or more probes. +¼ probe copy number normal (two copies present),– ¼ complete deletion of
target gene, 7¼hemizygous deletion (one copy present).
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normal cells will influence the results. The complexity of the
tumour genome must also be taken in to consideration, as any
abnormal copy number of control probe target sequences will
result in the allocation of an inaccurate test probe sequence copy
number. Therefore it is advisable to confirm the suitability of the
internal control probe data set for a group of tumours. For
example, in this study of ESFT, where gain of chromosome 8 is a
common event (Armengol et al, 1997; Tarkkanen et al, 1999;
Hattinger et al, 2002), the two control probes on chromosome 8
were excluded. The main advantage of MLPA over PCR-based
techniques is the ability to identify single copy deletions.
No correlation was observed between homozygous deletion of
CDKN2A and overall survival, event-free survival or the presence of
metastatic disease at diagnosis. Furthermore, deletion of one copy
of CDKN2A (5% of primary ESFT) was rare. These observations are
in contrast to previous studies in ESFT. In a study of 24 ESFT,
patients with tumours that had a mutation/deletion of p16 (4/24;
17%) had a worse event-free survival than those without (P¼0.019;
Tsuchiya et al, 2000), and in a second study, patients with deletions
of p16 (7/39; 18%) were shown to have a worse disease-specific
survival than those without (P¼0.001; Wei et al, 2000). In both
these studies, deletions were detected by Southern blot of total DNA
from tumours compared to MLPA analysis of DNA extracted from
isolated tumour cells. Using MLPA, homozygous deletion of the
CDKN2A gene was observed in four primary ESFT; this correlated
with loss of p16/p14
ARF mRNA expression. In the two tumours with
a single gene copy loss p16/p14
ARF mRNA was expressed,
suggesting that the remaining copy was not mutated. In all the
remaining tumours p16/p14
ARF was expressed, although the level of
expression was heterogeneous. This heterogeneity could not be
attributed to hypermethylation of the p16 promoter; whether
hypermethylation of the p14
ARF promoter is an important
mechanism of downregulating p14
ARF expression remains to be
seen. Other studies have reported p16 promoter hypermethylation
in ESFT to be rare; 1/24 (4%; Tsuchiya et al, 2000) and 2/19 (10%;
Lopez-Guerrero et al, 2001). Heterogeneity of expression might
therefore be effected through expression of wild-type p53, which
can downregulate transcription from the p14
ARF and p16 promoter
(Robertson and Jones, 1998), pRb hyperphosphorylation (Chatterjee
et al, 2004) or overexpression of the bmi-1 gene (Jacobs et al,
1999). Homozygous and single copy deletions of the MTAP gene
were observed in ESFT cell lines and primary tumour; homozygous
deletions (but not single copy deletions) have previously been
described with similar frequency to this study (Huang et al, 2005).
The MTAP gene was always co-deleted with CDKN2A, consistent
with previous data (Jacobs et al, 1999).
Patients with tumours that expressed high levels of p16/p14
ARF
mRNA (assessed by primers that amplified CDKN2A exons 2 and
3) had a significantly worse event-free survival than patients with
tumours that expressed low levels of p16/p14
ARF (P¼0.046, log-
rank test). This is unexpected as one might predict that reduced
levels of p16 would result in deregulated activation of cyclin-
dependent kinase 4/6 resulting in uncontrolled cell-cycle transition
through the Rb pathway, leading to a higher tumour growth rate.
However, high levels of p16 mRNA expression have been related to
a shorter event-free survival in acute lymphoid leukaemia (Mekki
et al, 1999), breast cancer (Hui et al, 2000) and neuroblastoma
(Omura-Minamisawa et al, 2001), and loss of p16 protein
expression has previously been associated with the presence of
metastatic disease at diagnosis in primary ESFT (P¼0.026, n¼20;
Maitra et al, 2001). Interestingly, we found no correlation between
p16 protein expression and outcome. In contrast to studies of p16
mRNA, previous studies have reported overexpression of p16
protein to be predictive of improved prognosis in oropharyngeal
squamous-cell cancer (Weinberger et al, 2004), vulvar carcinoma
(Knopp et al, 2004) and colorectal carcinoma (Zhao et al, 2003; Cui
et al, 2004), whereas high levels of p16 protein expression have
been associated with shorter event-free survival in prostate cancer
(Lee et al, 1999). Whether these inconsistencies reflect tumour-
specific roles of p16, or differences in the prognostic significance
of mRNA and protein remain to be seen. In this study, expression
of p16 protein did not correlate with p16/p14
ARF mRNA levels;
however, homozygous deletion of the CDKN2A gene resulted in
A
CD
B
Figure 4 Expression of p16 protein detected by immunohistochemistry. Immunohistochemistry was performed on frozen primary ESFT (n¼37) and p16
protein detected using the CSA System. Tumours were negative (A), expressed in focal hotspots (B) or throughout the tumour (C). Homozygous deletion
of CDKN2A correlated with loss of p16 protein expression in 3/4 tumours. Immunohistochemistry performed in the absence of primary antibody controlled
for nonspecific binding of the primary antibody (D). Magnification  400.
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of tumour cells were negative for p16 expression; however, a small
clone of cells expressed p16 protein, and we predict this clone of
cells must have been absent in adjacent tumour sections that were
analysed by MLPA for CDKN2A gene status. p16 protein and
mRNA levels have previously been shown not to correlate in a
study of patients with adult T-cell leukaemia; tumours with high
levels of p16 mRNA expression were shown to lack expression of
p16 protein and showed a significantly shorter survival than
patients with tumours that expressed p16 protein (Takasaki et al,
2003). This discrepancy may reflect the rapid post-translational
degradation of p16 protein, which requires further investigation. It
will also be important to investigate the expression and prognostic
significance of p14
ARF mRNA and protein; previous studies have
shown no correlation between p14
ARF protein expression and
outcome in ESFT (Maitra et al, 2001) although in squamous-cell
carcinoma loss of expression is reported to predict a worse overall
and event-free survival (Kwong et al, 2005).
In summary, we have shown high levels of p16/p14
ARF mRNA in
tumours taken at diagnosis predict a significantly worse event-free
survival in patients with ESFT. However, p16 protein expression
was not prognostically significant. The disparity in these results
may be explained by the complex interaction of multiple cell-cycle
regulatory proteins on tumour proliferation and progression. The
inconsistency of data in the literature on the profile and prognostic
significance of p16 and p14
ARF gene status, mRNA and protein
expression in cancer emphasises the importance of investigating
these and interacting cell-cycle regulatory genes in the same
clinical samples, according to standardised methods, in a
prospective clinical outcome study. High-throughput methods
such as MLPA may facilitate such analyses.
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